06 August 2018
Visiongain has launched a new pharma report Cancer Immunotherapy Market Report : Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer
The future of the cancer immunotherapy market looks promising, as a number of new and innovative therapies are coming on to the market. Monoclonal antibodies (mAbs) held the largest market share. Monoclonal antibodies have gained significant attention in recent years due to their target specificity, high efficacy and less toxicity. Due to the success of immunotherapeutics in curing cancer, research companies are now focused on the development of immunotherapeutics for cancer treatments. Demand for personalized medicine is owing to the growth of therapeutic antibodies.
The lead analyst of the report commented - “The global cancer immunotherapy market will see strong growth over the forecast period. The approval of advance therapeutics is paradigm shifting in the field from conventional chemotherapies to immunotherapies. Increased R&D funding coupled with rising prevalence of cancer and continued commitment by government bodies and healthcare providers will propel demand and accentuate growth in the market. However, challenges in clinical trials, high costs and changes in reimbursement policies will restrain the market.
Asia Pacific is expected to experience the fastest growth as more multinational companies such as AstraZeneca, Merck and Co. and Pfizer invest in the region through mergers and acquisitions to retain their market share and thus diversify their product portfolio.’’
Leading companies featured in the report include Roche AstraZeneca, Merck & Co., Novartis, Adaxis Inc, Bristol-Myers Squibb (BMS), Bayer AG, Roche, Eli Lilly and Co. and Medtronic Plc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.